Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia.

British Journal of Haematology
Matthias FloethLinus Angenendt

Abstract

The low-density lipoprotein receptor (LDLR) is a membrane receptor that mediates the endocytosis of low-density lipoprotein (LDL). Uptake of LDL has been proposed to contribute to chemotherapy resistance of acute myeloid leukaemia (AML) cell lines in vitro. In the present study, we analysed LDLR expression and survival using bone marrow biopsies from 187 intensively treated patients with AML. Here, increasing LDLR expression was associated with decreasing overall (58·4%, 44·2%, and 24·4%; P = 0·0018), as well as event-free survival (41·7%, 18·1%, and 14·3%; P = 0·0077), and an increasing cumulative incidence of relapse (33·9%, 55·1%, and 71·4%; P = 0·0011). Associations of LDLR expression with survival were confirmed in 557 intensively treated patients from two international validation cohorts. In the analytic and validation cohorts, LDLR expression remained associated with outcome in multivariable regression analyses including the European LeukemiaNet genetic risk classification. Thus, LDLR predicts outcome of patients with AML beyond existing risk factors. Furthermore, we found low expression levels of LDLR in most healthy tissues, suggesting it as a promising target for antibody-based pharmacodelivery approaches in AML.

References

Apr 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·S VitolsK Söderberg-Reid
Jul 14, 1998·Nature Medicine·J KononenO P Kallioniemi
Apr 16, 2004·The New England Journal of Medicine·Peter J M ValkRuud Delwel
Jun 15, 2005·Annual Review of Biochemistry·Hyesung Jeon, Stephen C Blacklow
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
May 30, 2014·Nature·Min-Sik KimAkhilesh Pandey
Feb 13, 2015·Proceedings of the National Academy of Sciences of the United States of America·Fabienne GuillaumondSophie Vasseur
Nov 27, 2015·FEBS Letters·Ryuji YamaguchiKiichi Hirota
Dec 4, 2015·Nature Protocols·Nicole BäumerSebastian Bäumer
Mar 23, 2017·Molecular Therapy. Nucleic Acids·Oliver BrabetzJan-Henrik Mikesch
Feb 3, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Margaretha G M RoemerMargaret A Shipp
Jun 2, 2018·The European Respiratory Journal·Jan-Henrik MikeschMaria-Francisca Arteaga
Jul 20, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey E LancetBruno C Medeiros

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.